Modulating Myeloperoxidase Expression via Gene Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting Myeloperoxidase (MPO) activity are limited as they primarily target the heme active site, failing to address other MPO domains and can lead to unwanted effects such as vasculitis, and require continuous administration to manage ongoing neutrophil production.
Innovation Solution
Modulating MPO expression and activity in undifferentiated bone marrow cells using gene editing compounds, allowing for targeted modulation of MPO in the immune system, which can then affect MPO levels and activity in other tissues, including the brain, to treat MPO-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current MPO inhibitors targeting the heme active site are used, then MPO activity is inhibited, but vasculitis and other unwanted effects occur
Solution Approach 1:
The patent applies local quality by targeting specific MPO domains (hinge region, N-terminal domain) rather than the heme active site, creating inhibitors with different binding locations that achieve MPO inhibition without triggering vasculitis. This localized targeting approach allows selective modulation of MPO function while avoiding harmful systemic effects.
Solution Approach 2:
Instead of targeting the traditional heme active site, the patent inverts the approach by targeting other critical domains of MPO (hinge region, N-terminal domain). This inverse targeting strategy achieves therapeutic inhibition while avoiding the harmful effects associated with heme site blockade.
2Reliability
If current MPO inhibitors are administered continuously, then ongoing neutrophil production is managed, but the treatment complexity and duration increase
Solution Approach 1:
The patent applies preliminary action by administering inhibitors that target MPO domains involved in protein stability and degradation. By blocking degradation pathways at the hinge region or N-terminal domain, the treatment achieves sustained inhibition of MPO function without requiring continuous dosing, as the effect persists through the natural turnover of the targeted protein domains.
3Reliability
If heme active site inhibitors are used, then MPO catalytic activity is blocked, but other MPO domains remain unaffected
Solution Approach 1:
The patent applies universality by developing inhibitors that target multiple functional domains of MPO (hinge region, N-terminal domain) rather than solely the heme active site. These multi-domain targeted inhibitors provide comprehensive coverage of MPO functions including catalysis, protein-protein interactions, and structural stability, achieving broader therapeutic effectiveness.
Data Source
AI summary
The present invention relates to methods of modulating the expression and/or activity of Myeloperoxidase (MPO) in a mammalian subject, by modulating ex vivo and/or in vivo MPO levels and/or activity in undifferentiated bone marrow (BM) cells of the subject. The invention further provides therapeutic methods and compositions for treating MPO-related disorders.